Correlation Between Veracyte and Lexeo Therapeutics,

Can any of the company-specific risk be diversified away by investing in both Veracyte and Lexeo Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Veracyte and Lexeo Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Veracyte and Lexeo Therapeutics, Common, you can compare the effects of market volatilities on Veracyte and Lexeo Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Veracyte with a short position of Lexeo Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Veracyte and Lexeo Therapeutics,.

Diversification Opportunities for Veracyte and Lexeo Therapeutics,

0.8

Correlation Coefficient

Veracyte  Lexeo Therapeutics,

Very poor diversification

The 3 months correlation between Veracyte and Lexeo is 0.8. Overlapping area represents the amount of risk that can be diversified away by holding Veracyte and Lexeo Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lexeo Therapeutics, and Veracyte is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Veracyte are associated (or correlated) with Lexeo Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lexeo Therapeutics, has no effect on the direction of Veracyte i.e., Veracyte and Lexeo Therapeutics, go up and down completely randomly.

Pair Corralation between Veracyte and Lexeo Therapeutics,

Given the investment horizon of 90 days Veracyte is expected to generate 0.4 times more return on investment than Lexeo Therapeutics,. However, Veracyte is 2.52 times less risky than Lexeo Therapeutics,. It trades about -0.1 of its potential returns per unit of risk. Lexeo Therapeutics, Common is currently generating about -0.04 per unit of risk. If you would invest  4,000  in Veracyte on December 29, 2024 and sell it today you would lose (890.00) from holding Veracyte or give up 22.25% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Strong
Accuracy	100.0%
Values	Daily Returns

Veracyte  vs.  Lexeo Therapeutics, Common

Veracyte

Risk-Adjusted Performance

Very Weak

Over the last 90 days Veracyte has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Lexeo Therapeutics,

Risk-Adjusted Performance

Very Weak

Over the last 90 days Lexeo Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of conflicting performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Veracyte and Lexeo Therapeutics,

The main advantage of trading using opposite Veracyte and Lexeo Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Veracyte position performs unexpectedly, Lexeo Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lexeo Therapeutics, will offset losses from the drop in Lexeo Therapeutics,'s long position.

The idea behind Veracyte and Lexeo Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.